Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024 08:00 ET
|
Standard BioTools Inc.
Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Standard BioTools to Participate in Upcoming Investor Conferences
August 06, 2024 16:01 ET
|
Standard BioTools Inc.
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools Announces Senior Leadership Changes
July 31, 2024 16:02 ET
|
Standard BioTools Inc.
Standard BioTools Announces Senior Leadership Changes
Standard BioTools Reports Second Quarter 2024 Financial Results
July 31, 2024 16:01 ET
|
Standard BioTools Inc.
Standard BioTools Reports Second Quarter 2024 Financial Results
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
July 17, 2024 08:01 ET
|
Standard BioTools Inc.
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers
May 28, 2024 16:01 ET
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSAXT system from Carterra®, a leading...
Standard BioTools to Participate in Upcoming Investor Conferences
May 22, 2024 16:01 ET
|
Standard BioTools Inc.
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2024 08:00 ET
|
Standard BioTools Inc.
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Standard BioTools Reports First Quarter 2024 Financial Results
May 08, 2024 16:01 ET
|
Standard BioTools Inc.
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025Delivered pro forma combined revenue of $46.2 million,...
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
April 25, 2024 08:01 ET
|
Standard BioTools Inc.
Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on...